Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

Sponsor
GlaxoSmithKline
Study ID
NCT06655818
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with other anti-cancer treatments (in each sub-study), and to establish the recommended Phase 2 dose for each combination treatment to explore in the cohort expansion phase. This study is a sub study of the Master protocol (NCT04126200).

Key Dates

First listed
Oct 23, 2024
Start date
Mar 9, 2021
Status verified
Feb 2025
Primary completion
Feb 14, 2024
Completion
Feb 14, 2024

Study Design

Enrollment
4 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Belantamab mafodotin + Dostarlimab

Primary Outcome Measure

DE Phase: Number of Participants With Dose Limiting Toxicities (DLT) [ Time Frame: Up to 21 days ]

Related Studies